What is hidden from the view. The problem of chronic and delayed toxicity after immunotherapy based on clinical cases and literature review

The emergence of immunotherapy has revolutionized the treatment approaches of numerous malignancies. Patients that previously faced a prognosis of only a few months left to live can now enjoy extended lifespans for several years. Nevertheless, it is crucial to acknowledge that immunotherapy carries its own spectrum of adverse events. Notably, the issue of immune-related toxicity is progressively gaining prominence with each passing year. A distinctive feature of these immune-related adverse events is their propensity to transition into chronic conditions, with some manifesting long after discontinuation of immunotherapy. Given the current incorporation of adjuvant immunotherapy regimens in clinical guidelines, it becomes imperative to direct heightened attention towards the challenges associated with chronic and delayed toxicity of immunotherapy.